Long-term therapy with antiretroviral (ARV) agents in HIV-infected patients often results in failure to suppress the viral load. Imperfect adherence and drug susceptibility to prescribed antiviral drugs are important factors explaining the resurgence of virus. A better understanding of the...

The study of HIV dynamics is one of the most important developments in recent AIDS research. It has led to a new understanding of the pathogenesis of HIV infection. Although important findings in HIV dynamics have been published in prestigious scientific journals, the statistical methods for...

Interval estimation of the x th effective dose (ED x ), where x is a prespecified percentage, has been the focus of interest of a number of recent studies, the majority of which have considered the case in which a logistic dose-response curve is correctly assumed. In this paper, we focus our...

In clinical practice, the profile of each subject's CD4 response from a longitudinal study may follow a 'broken stick' like trajectory, indicating multiple phases of increase and/or decline in response. Such multiple phases (changepoints) may be important indicators to help quantify treatment...

A virologic marker, the number of HIV RNA copies or viral load, is currently used to evaluate antiretroviral (ARV) therapies in AIDS clinical trials. This marker can be used to assess the antiviral potency of therapies, but may be easily affected by clinical factors such as drug exposures and...

Muller & Schmitt (1990) have considered the question of how to choose the number of doses for estimating the median effective dose (ED50) when a probit dose-response curve is correctly assumed. However, they restricted their investigation to designs with doses symmetrical about the true ED50. In...

This article explores Bayesian joint models of event times and longitudinal measures with an attempt to overcome departures from normality of the longitudinal response, measurement errors, and shortages of confidence in specifying a parametric time-to-event model. We allow the longitudinal...